Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo
/in Acute Leukemia, International Publications, Newcastle Disease Virus /von 2011-11-30 / Leuk. Res. 2012 May;36(5):634-45Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
/in International Publications, Newcastle Disease Virus, NSCLC /von 2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-64Safety and clinical usage of newcastle disease virus in cancer therapy
/in International Publications, Newcastle Disease Virus /von 2011-10-26 / J. Biomed. Biotechnol. 2011;2011:718710Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98Apoptin enhances the oncolytic properties of Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2011-08-24 / Intervirology 2012;55(4):276-86Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)Oncolytic viruses for the treatment of neuroendocrine tumors
/in International Publications, Newcastle Disease Virus /von 2011-05-30 / Horm. Metab. Res. 2011 Nov;43(12):877-83IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de